A novel palmitoylethanolamide formulation improves hyperalgesia and red cell instability in murine sickle cell disease
1. Oral, water-dispersible palmitoylethanolamide is rapidly bioavailable and improves hematological markers of sickle cell disease. 2. Oral palmitoylethanolamide reduces inflammation as well as chronic and acute hyperalgesia in sickle cell disease.
Authors
- Natalie R. Garcia
- Donovan A. Argueta (ORCID: https://orcid.org/0000-0002-8234-141X)
- Alex Mabou Tagne (ORCID: https://orcid.org/0000-0003-3986-8344)
- Daniele Piomelli
- Kalpna Gupta
Institutions
- University of Minnesota (US)
- University of California, Irvine (US)
- University of Minnesota Medical Center (US)
- Minnesota Oncology (US)
Publication Details
- Journal
- Blood Vessels Thrombosis & Hemostasis
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1016/j.bvth.2026.100136
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00